About Lisata Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.lisata.com/
Frequently Asked Questions
What is the 52-week range for LSTA?
The 52-week high is $5.07 and the 52-week low is $0.9875.
What is the P/E ratio for LSTA?
The P/E ratio data is currently unavailable.
What is the dividend yield for LSTA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -75.10%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -4478.24%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.10.
Analyst Recommendation Trends
Wall Street analyst consensus for LSTA over the last few months:
Latest LSTA News
Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions
Marea Therapeutics, a subsidiary of Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), said data from the Phase 2b TYDAL study of its lead candidate MAR001 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions 2026 in Chicago. MAR001 is an...
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic functionSOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-g
MARKETS LIVE: Wall Street set for weaker open ahead of Trump-Xi talks
Dow Jones futures: 51,672.00 points, down 201 points. S&P 500 futures: 7,723.25 points, down 49.25 points. Nasdaq 100 futures: 30,437.75 points, down 327 points. FTSE 100: 10,722.01 points, up 16.75 points. 8:15 EST: Wall Street preview Dow Jones futures is down 201 points at...
Lisata Therapeutics (LSTA) Buys Marea and Signs $225M Financing. Is the Dilution Worth it?
Lisata Therapeutics, Inc. (NASDAQ:LSTA) announced on September 17 that it completed its acquisition of Marea Therapeutics and signed a definitive agreement for a concurrent private placement expected to raise approximately $225 million gross. Financing completion was expected on September 18, subject to customary closing conditions. Following both transactions, legacy equity holders of Lisata Therapeutics, Inc. […]
Lisata deal propels Marea’s drug pipeline to Wall Street
Marea’s acquisition by Lisata, alongside a $225 million financing deal, will back development of a pair of medicines in mid-stage testing for cardiovascular and endocrine conditions.
Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has acquired Marea Therapeutics, a clinical-stage biotech developing next-generation medicines for cardioendocrine diseases. The companies also entered a private placement financing agreement expected to raise approximately $225 million in gross...
Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in private financing for Phase 2 clinical trials.
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is advancing to a Phase 2 study Concurrent financing of $225 million from leading life sciences investors and other institutional investors projected to fund operations into 2028 LIBERTY CORNER, N.J., Sept. 17,
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Aethlon Medical (NASDAQ:AEMD) shares rose 330.8% to $6.16 during Thursday's regular session. The market value of their outstanding shares is at $1.0 million. bioAffinity Technologies (NASDAQ:BIAF) shares
Lisata Acquires Marea Therapeutics And Secures $225M Financing To Advance Next-Generation Medicines For Cardioendocrine Diseases
Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseasesMarea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG)
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-01-09 | Imam Tariq | +7,000 | - | - |
| 2026-01-09 | Imam Tariq | -513 | $1.97 | $1,011 |
| 2026-01-09 | Imam Tariq | -747 | $1.97 | $1,472 |
| 2026-01-09 | Imam Tariq | -840 | $1.97 | $1,655 |
| 2026-01-09 | Imam Tariq | -1,401 | $1.97 | $2,760 |
| 2026-01-09 | Imam Tariq | +15,000 | - | - |
| 2026-01-09 | Nisco James | +7,000 | - | - |
| 2026-01-09 | Nisco James | -781 | $1.97 | $1,539 |
| 2026-01-09 | Nisco James | -1,137 | $1.97 | $2,240 |
| 2026-01-09 | Nisco James | -2,131 | $1.97 | $4,198 |
| 2026-01-09 | Nisco James | -2,131 | $1.97 | $4,198 |
| 2026-01-09 | Nisco James | +15,000 | - | - |
| 2026-01-09 | Buck Kristen K | +13,000 | - | - |
| 2026-01-09 | Buck Kristen K | -2,147 | $1.97 | $4,230 |
| 2026-01-09 | Buck Kristen K | -3,221 | $1.97 | $6,345 |
| 2026-01-09 | Buck Kristen K | -2,982 | $1.97 | $5,875 |
| 2026-01-09 | Buck Kristen K | -2,982 | $1.97 | $5,875 |
| 2026-01-09 | Buck Kristen K | +25,000 | - | - |
| 2026-01-09 | Flowers Cynthia Louise | +30,456 | - | - |
| 2026-01-09 | BROWN GREGORY B | +30,456 | - | - |
| 2026-01-09 | Mazzo David J | +40,000 | - | - |
| 2026-01-09 | Mazzo David J | -7,854 | $1.97 | $15,472 |
| 2026-01-09 | Mazzo David J | -12,224 | $1.97 | $24,081 |
| 2026-01-09 | Mazzo David J | -10,515 | $1.97 | $20,715 |
| 2026-01-09 | Mazzo David J | -10,503 | $1.97 | $20,691 |
| 2026-01-09 | Mazzo David J | +81,000 | - | - |
| 2026-01-09 | AZAB MOHAMMAD | +30,456 | - | - |
| 2026-01-09 | HENSON HEIDI | +30,456 | - | - |
| 2026-01-09 | KLOSK STEVEN M | +30,456 | - | - |